Product Information
IMIQUIMOD 5% CREAM PACKET is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $12.1655 per EA under NDC 45802036853. Its NADAC has been published 467 times since Nov 28, 2013.
FDA first approved this application on Sep 7, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5 mg/.25g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802036853
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
IMIQUIMODApproval Type
Generic (ANDA)
FDA Application
ANDA078837FDA Approved
9/7/2010
TE Code
AB
On Market Since
11/9/2010
Pharmacological Classes
Price Statistics
The NADAC for IMIQUIMOD 5% CREAM PACKET has been published 467 times since Nov 28, 2013, and over the history we have for it it has declined 14.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.1655 per EA |
|---|---|
| All-time high | $14.2358 (Dec 11, 2013) |
| All-time low | $8.4277 (Feb 17, 2016) |
| 52-week high | $12.1655 |
| 52-week low | $10.2092 |
| Median price | $11.6197 |
| Average price | $11.6386 |
| Largest weekly change | +26.0% (Mar 23, 2016) |
| Weeks tracked | 467 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 95% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Imiquimod market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMIQUIMOD 5% CREAM PACKET?
The current National Average Drug Acquisition Cost (NADAC) for IMIQUIMOD 5% CREAM PACKET, manufactured by Padagis Israel Pharmaceuticals Ltd, is $12.1655 per EA (NDC 45802036853), effective Sep 30, 2026.
How has the price of IMIQUIMOD 5% CREAM PACKET changed over time?
Over the history we have for it, the NADAC for IMIQUIMOD 5% CREAM PACKET has declined 14.5%. It has been tracked across 467 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IMIQUIMOD 5% CREAM PACKET?
Since Nov 28, 2013, the NADAC for IMIQUIMOD 5% CREAM PACKET has ranged from a low of $8.4277 (Feb 17, 2016) to a high of $14.2358 (Dec 11, 2013), with a median of $11.6197 per EA.
Are there cheaper alternatives to IMIQUIMOD 5% CREAM PACKET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMIQUIMOD 5% CREAM PACKET, is $0.6099 per EA — about 95% below IMIQUIMOD 5% CREAM PACKET.
Who manufactures IMIQUIMOD 5% CREAM PACKET?
IMIQUIMOD 5% CREAM PACKET (NDC 45802036853) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.